ReviewBiomolecules2021
A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07243470 (A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors
Who cites it
12 citing papers in PubMed.
- From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.International journal of molecular sciences · 2026Review
- Metabolic reprogramming in sepsis-associated encephalopathy: emerging mechanisms, candidate biomarkers, and future therapeutic directions.Frontiers in medicine · 2026Review
- Identification of a prognostic signature consisting of three macrophage-related genes for glioblastoma based on bulk and single-cell transcriptomes analyses.Annals of medicine · 2025Article
- Integrating artificial intelligence with nanodiagnostics for early detection and precision management of neurodegenerative diseases.Journal of nanobiotechnology · 2025Review
- Establishment of a machine learning model for predicting splenic hilar lymph node metastasis.NPJ digital medicine · 2025Article
- Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information.Experimental hematology & oncology · 2022Review
- Application of non-negative matrix factorization in oncology: one approach for establishing precision medicine.Briefings in bioinformatics · 2022Review
- Review
- Applications of Artificial Intelligence Based on Medical Imaging in Glioma: Current State and Future Challenges.Frontiers in oncology · 2022Review
- Machine Learning: A New Prospect in Multi-Omics Data Analysis of Cancer.Frontiers in genetics · 2022Review
- Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics.Journal of personalized medicine · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Although the incidence of central nervous system (CNS) cancers is not high, it significantly reduces a patient's quality of life and results in high mortality rates. A low incidence also means a low number of cases, which in turn means a low amount of information. To compensate, researchers have tried to increase the amount of information available from a single test using high-throughput technologies. This approach, referred to as single-omics analysis, has only been partially successful as one type of data may not be able to appropriately describe all the characteristics of a tumor. It is presently unclear what type of data can describe a particular clinical situation. One way to solve this problem is to use multi-omics data. When using many types of data, a selected data type or a combination of them may effectively resolve a clinical question. Hence, we conducted a comprehensive survey of papers in the field of neuro-oncology that used multi-omics data for analysis and found that most of the papers utilized machine learning techniques. This fact shows that it is useful to utilize machine learning techniques in multi-omics analysis. In this review, we discuss the current status of multi-omics analysis in the field of neuro-oncology and the importance of using machine learning techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.